Clinical Trial Update: Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) [Phase 2]

View source ↗

Summary

Phase II clinical trial update for Puxitatug Samrotecan (AZD8205) in advanced, recurrent or metastatic Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I); tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• Puxitatug Samrotecan (AZD8205)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING